Evolent Health, Inc.

Evolent Health, Inc.

EVH
Evolent Health, Inc.US flagNew York Stock Exchange
4.80
USD
+0.22
- -
539.91MMarket Cap
Evolent Health, Inc.
EVH
(New York Stock Exchange)

Recent

price

4.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.67
- -
3.86
5.64
6.76
8.11
8.34
10.89
10.55
14.43
17.65
22.28
16.43
16.66
Revenue per Share
0.52
-0.66
13.23
-3.55
-0.94
-0.68
-3.67
-3.94
-0.44
-0.2
-1.28
-0.81
-5.07
-4.71
Basic EPS, GAAP
-0.63
- -
-0.99
-1.13
-0.87
-0.78
-0.95
-0.54
-0.13
-0.94
1.02
-0.05
0.04
0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
0.24
0.02
0.16
0.17
0.18
0.1
0.06
Dividend per Share
- -
-0.68
12.23
3.27
1.35
0.66
-3.05
-6.93
-7.27
-6.46
-6.45
-6.8
-11.51
-11.83
Book Value per Share
-0.04
-0.05
6.47
0.59
2.75
1.11
0.59
0.07
-0.14
-3.27
-7.2
-7.12
-7.57
-7.65
Tangible Book Value per Share
38
38
25
45
64
77
82
85
86
94
111
115
114
113
Basic Weighted Avg Shares
26
- -
97
254
435
627
687
925
908
1,352
1,964
2,555
1,876
1,889
Sales/Revenue/Turnover
-82.41
- -
-44.36
-31.04
-16.65
-8.23
-17.85
-4.67
-3.21
-1.47
-1.07
-0.55
-1.06
-1.61
Operating Margin (%)
1
- -
7
17
32
45
61
61
60
67
123
118
116
113
Depreciation Expense
20
-25
332
-160
-61
-53
-302
-334
-38
-19
-113
-62
-535
-497
Net Income, GAAP
0.04
- -
6.84
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
78
- -
343.21
-62.84
-13.95
-8.4
-43.95
-36.15
-4.14
-1.42
-5.76
-2.41
-28.49
-26.29
Profit Margin (%)
51
- -
125
133
245
219
36
144
78
45
9
-108
121
121
Working Capital
- -
- -
- -
120
121
221
363
326
273
469
635
515
974
977
LT Debt
31
-2
935
912
1,046
1,189
929
620
694
859
1,068
1,001
415
396
Total Equity
- -
- -
-8.59
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
121.82
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-70.29
-51.85
-76.56
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
23
15
9
LT Borrowings
1,055
971
973
LT Finance Leases
4
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
112
112
112
Market Capitalization
974
457
258

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
570
506
502
Cash, Cash Equivalents & STI
117
152
142
Accounts Receivable, Net
387
310
314
Inventories
- -
- -
- -
Total Current Liabilities
430
385
381
Payables & Accruals
133
126
108
ST Debt
23
15
9
Deferred Revenue
2
1
1

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.39%
-0.93%
-58.53%
Free Cash Flow
20.93%
19.89%
-177.59%
Net Income, GAAP
133.49%
214.8%
767.39%
Sales/Revenue/Turnover
41.77%
19.18%
-26.56%
Total Cash Common Dividend
- -
196.29%
187.45%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
640
647
621
647
2,555
2025
484
444
480
469
1,876
2026
496
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.22
-0.06
-0.27
-0.27
-0.81
2025
-0.63
-0.44
-0.24
-3.84
-5.07
2026
-0.24
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.04
0.04
0.04
0.18
2025
0.04
0.04
0.02
- -
0.1
2026
- -
- -
- -
- -
- -
Business
Evolent Health, Inc. (NYSE: EVH) provides specialty care management services to health plans and providers in oncology, cardiology, musculoskeletal, and primary care markets across the United States. The company offers an integrated technology platform including Identifi for data aggregation, analytics, care workflows, and patient engagement; clinical program management encompassing clinical pathways and decision support; care management services; risk adjustment; pharmacy benefits management; population health management; value-based care enablement; revenue cycle management; and advance care planning through Vital Decisions. Founded in 2011 and headquartered in Arlington, Virginia, Evolent partners with leading payers and providers to align care with clinical evidence, member preferences, and seamless delivery across settings. In September 2025, Evolent agreed to sell its accountable care organization business, Evolent Care Partners, to Privia Health for $100 million in cash plus up to $13 million contingent on 2025 Medicare Shared Savings Program performance, enabling debt reduction and a strategic focus on core specialty care management. The company announced more than $500 million in newly contracted annualized revenue set to launch in 2026 during its third quarter 2025 earnings release in November 2025, reflecting strong growth momentum. Evolent reported fiscal 2024 revenue of approximately $1.96 billion, up 17.8% year-over-year, with continued expansion in value-based care solutions.

Company News

MCPAPIChat
  • Agentic AI Powers U.S. Healthcare Stocks

  • Evolent Health Q1 Earnings Call Highlights

  • Evolent Health, Inc. (EVH) Q1 2026 Earnings Call Transcript

  • Compared to Estimates, Evolent Health (EVH) Q1 Earnings: A Look at Key Metrics

  • Evolent Health (EVH) Reports Q1 Loss, Misses Revenue Estimates

  • Evolent Announces First Quarter 2026 Results

  • Evolent To Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

  • Evolent Health, Inc (NYSE:EVH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

  • Evolent announces appointment of Archie Mayani as chief product officer

  • 8 Knots Management LLC Lowers Position in Evolent Health, Inc $EVH

  • Evolent to Participate in Upcoming Investor Conferences

  • Evolent Health: Cheap, Levered, But Ready To Rebound

  • Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript

  • Compared to Estimates, Evolent Health (EVH) Q4 Earnings: A Look at Key Metrics

  • Evolent Health (EVH) Q4 Earnings Top Estimates

  • Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

  • Evolent Health (NYSE:EVH) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?

  • Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026

  • Evolent Health, Inc (NYSE:EVH) Given Consensus Recommendation of “Moderate Buy” by Analysts

  • Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08